JPWO2021230325A1 - - Google Patents
Info
- Publication number
- JPWO2021230325A1 JPWO2021230325A1 JP2022522202A JP2022522202A JPWO2021230325A1 JP WO2021230325 A1 JPWO2021230325 A1 JP WO2021230325A1 JP 2022522202 A JP2022522202 A JP 2022522202A JP 2022522202 A JP2022522202 A JP 2022522202A JP WO2021230325 A1 JPWO2021230325 A1 JP WO2021230325A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020085420 | 2020-05-14 | ||
| JP2020085420 | 2020-05-14 | ||
| PCT/JP2021/018252 WO2021230325A1 (ja) | 2020-05-14 | 2021-05-13 | １，４，５，６－テトラヒドロピリミジン－２－アミン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021230325A1 true JPWO2021230325A1 (https=) | 2021-11-18 |
| JP7661969B2 JP7661969B2 (ja) | 2025-04-15 |
Family
ID=78524455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522202A Active JP7661969B2 (ja) | 2020-05-14 | 2021-05-13 | １，４，５，６－テトラヒドロピリミジン－２－アミン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230192661A1 (https=) |
| EP (1) | EP4151632A4 (https=) |
| JP (1) | JP7661969B2 (https=) |
| KR (1) | KR20230011967A (https=) |
| CN (1) | CN115551846B (https=) |
| AU (1) | AU2021270095A1 (https=) |
| BR (1) | BR112022023058A2 (https=) |
| CA (1) | CA3182964A1 (https=) |
| MX (1) | MX2022014200A (https=) |
| WO (1) | WO2021230325A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023085396A1 (ja) * | 2021-11-12 | 2023-05-19 | Ｕｂｅ株式会社 | アルポート症候群を治療または予防するための医薬組成物 |
| EP4733297A1 (en) * | 2023-06-22 | 2026-04-29 | Antibody Therapeutics, Inc. | Integrin-inhibiting small molecule compound |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997008145A1 (en) * | 1995-08-30 | 1997-03-06 | G.D. Searle & Co. | Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists |
| JP2002511462A (ja) * | 1998-04-10 | 2002-04-16 | ジー・ディー・サール・アンド・カンパニー | ビトロネクチンアンタゴニストとしてのヘテロ環式グリシルβ−アラニン誘導体 |
| JP2006514050A (ja) * | 2002-12-20 | 2006-04-27 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニスト誘導体としてのβ−アミノ酸化合物のＲ異性体 |
| JP2015524412A (ja) * | 2012-07-18 | 2015-08-24 | セントルイス ユニバーシティ | インテグリンアンタゴニストとしてのβアミノ酸誘導体 |
| JP2019500355A (ja) * | 2015-12-30 | 2019-01-10 | セントルイス ユニバーシティ | 汎インテグリンアンタゴニストとしてのメタ−アザ環式アミノ安息香酸誘導体 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA994406B (en) | 1998-03-04 | 2000-02-11 | Searle & Co | Meta-azacyclic amino benzoic acid and derivatives thereof. |
| US6372719B1 (en) | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
| US8716226B2 (en) | 2012-07-18 | 2014-05-06 | Saint Louis University | 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists |
-
2021
- 2021-05-13 KR KR1020227042726A patent/KR20230011967A/ko active Pending
- 2021-05-13 AU AU2021270095A patent/AU2021270095A1/en active Pending
- 2021-05-13 JP JP2022522202A patent/JP7661969B2/ja active Active
- 2021-05-13 MX MX2022014200A patent/MX2022014200A/es unknown
- 2021-05-13 CN CN202180034572.XA patent/CN115551846B/zh active Active
- 2021-05-13 US US17/924,942 patent/US20230192661A1/en active Pending
- 2021-05-13 WO PCT/JP2021/018252 patent/WO2021230325A1/ja not_active Ceased
- 2021-05-13 CA CA3182964A patent/CA3182964A1/en active Pending
- 2021-05-13 BR BR112022023058A patent/BR112022023058A2/pt unknown
- 2021-05-13 EP EP21803967.5A patent/EP4151632A4/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997008145A1 (en) * | 1995-08-30 | 1997-03-06 | G.D. Searle & Co. | Meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as integrin antagonists |
| JP2002511462A (ja) * | 1998-04-10 | 2002-04-16 | ジー・ディー・サール・アンド・カンパニー | ビトロネクチンアンタゴニストとしてのヘテロ環式グリシルβ−アラニン誘導体 |
| JP2006514050A (ja) * | 2002-12-20 | 2006-04-27 | ファルマシア・コーポレーション | インテグリン受容体アンタゴニスト誘導体としてのβ−アミノ酸化合物のＲ異性体 |
| JP2015524412A (ja) * | 2012-07-18 | 2015-08-24 | セントルイス ユニバーシティ | インテグリンアンタゴニストとしてのβアミノ酸誘導体 |
| JP2019500355A (ja) * | 2015-12-30 | 2019-01-10 | セントルイス ユニバーシティ | 汎インテグリンアンタゴニストとしてのメタ−アザ環式アミノ安息香酸誘導体 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115551846B (zh) | 2024-03-08 |
| JP7661969B2 (ja) | 2025-04-15 |
| EP4151632A4 (en) | 2024-04-24 |
| CA3182964A1 (en) | 2021-11-18 |
| AU2021270095A1 (en) | 2022-12-22 |
| EP4151632A1 (en) | 2023-03-22 |
| WO2021230325A1 (ja) | 2021-11-18 |
| MX2022014200A (es) | 2022-12-07 |
| US20230192661A1 (en) | 2023-06-22 |
| KR20230011967A (ko) | 2023-01-25 |
| BR112022023058A2 (pt) | 2022-12-20 |
| CN115551846A (zh) | 2022-12-30 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240315 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250214 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250304 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250317 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7661969 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |